Evidence map›Paper›PMID 25035774›Full record

ArticleInternational journal of clinical and experimental medicine2014

Relationship of PCNA, C-erbB2 and CD44s expression with tumor grade and stage in urothelial carcinomas of the bladder.

Ayhan Yıldırım, Mustafa Kösem, Ilyas Sayar, Ibrahim Gelincik, Alparslan Yavuz, Aliseydi Bozkurt, Unal Erkorkmaz, Irfan Bayram

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ayhan YıldırımDepartment of Pathology, Diyarbakır Pediatry and Gynecology Hospital Diyarbakır, Turkey.
Mustafa KösemDepartment of Pathology, Sakarya University Sakarya, Turkey.
Ilyas SayarDepartment of Pathology, Erzincan University Erzincan, Turkey.
Ibrahim GelincikDepartment of Pathology, Namık Kemal University Tekirdağ, Turkey.
Alparslan YavuzDepartment of Radiology, Yüzüncü Yıl University Van, Turkey.
Aliseydi BozkurtDepartment of Urology, Erzincan University Erzincan, Turkey.
Unal ErkorkmazDepartment of Biostatistic, Sakarya University Sakarya, Turkey.
Irfan BayramDepartment of Pathology, Yüzüncü Yıl University Van, Turkey.
Erzincan University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, the intention was to reveal the relationship of histological grade and stage with c-erbB2, CD44s, and PCNA immunoreactivity in bladder urothelial carcinomas (UC). In our study, we evaluated 46 items of transurethral resection material of patients submitted by YYU Faculty of Medicine, Main Department of Pathology, with a mass revealed in their bladder after clinical and radiological studies at our laboratories and who were diagnosed with urothelial carcinomas. PCNA, c-erbB2, and CD44s were applied in an immunohistochemical manner comprised from nine low-malignant potential papillary urothelial neoplasia, 23 low-grade papillary urothelial carcinoma, and 14 high-grade papillary urothelial carcinoma. Immunostaining was scored according to the percentage of positive cells. The immunohistochemical study demonstrated that the c-erbB2 and PCNA staining ratio increased when an increase occurred in stage and grade. The CD44s staining ratio decreased. C-erbB2, PCNA, and CD44s appear to be a useful marker in the assessment of the prognosis and treatment options in urothelial carcinomas.

Indexed as

CD44C-erbB2immunohistochemical studyPCNAUrothelial carcinomas

Identifiers

PMID25035774
PMCPMC4100960
OpenAlexW1788090983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.